AngioDynamics (NASDAQ:ANGO) Announces Quarterly Earnings Results

AngioDynamics (NASDAQ:ANGO) posted its quarterly earnings data on Tuesday. The medical instruments supplier reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.04, Briefing.com reports. AngioDynamics had a return on equity of 3.72% and a net margin of 17.47%. The company had revenue of $70.00 million during the quarter, compared to analyst estimates of $71.28 million. During the same period in the previous year, the business earned $0.22 EPS. AngioDynamics’s quarterly revenue was up .0% on a year-over-year basis. AngioDynamics updated its FY 2020
Pre-Market guidance to 0.10-0.15 EPS and its FY20 guidance to $0.10-0.15 EPS.

Shares of AngioDynamics stock opened at $15.05 on Friday. The stock has a market cap of $577.09 million, a P/E ratio of 18.13 and a beta of 0.65. The stock’s 50 day simple moving average is $15.66 and its 200-day simple moving average is $17.43. AngioDynamics has a 1-year low of $13.72 and a 1-year high of $25.48.

Several equities research analysts have commented on the company. TheStreet lowered AngioDynamics from a “c” rating to a “d+” rating in a research note on Thursday, October 3rd. ValuEngine upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. KeyCorp cut their price objective on AngioDynamics from $30.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, October 4th. Finally, BidaskClub lowered AngioDynamics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. AngioDynamics has an average rating of “Hold” and an average target price of $20.50.

In related news, CEO James C. Clemmer bought 15,000 shares of the stock in a transaction dated Friday, October 25th. The shares were acquired at an average cost of $14.19 per share, for a total transaction of $212,850.00. Following the acquisition, the chief executive officer now directly owns 260,418 shares in the company, valued at approximately $3,695,331.42. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 3.60% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Story: What is a stock split?

Earnings History for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.